The Lennox-Gastaut syndrome (LGS) is a recognizable form of epileptic encephalopathy characterized by multiple etiologies, multiple seizure types, cognitive deterioration, extensive electroencephalographic (EEG) changes awake and asleep, and resistance to antiepileptic drug (AED) treatment [1–3]. The long-term evolution of LGS is characterized by the possible abatement of EEG changes, especially awake, and by the persistence of invalidating seizures [4]. Traditional pharmacological options include valproate (VPA) and a combination of VPA and lamotrigine (LTG) [2].
22
DIC
DIC
0